[1] 卢兴国, 叶向军, 徐根波, 等.骨髓细胞与组织病理诊断学.北京:人民卫生出版社, 2020: 590.
[2] Jain P, Wang S, Patel KP, et al. Mast cell leukemia (MCL): clinico-pathologic and molecular features and survival outcome [J]. Leuk Res, 2017, 59:105-109. DOI: 10.1016/j.leukres.2017.05.018.
[3] Valent P, Sotlar K, Sperr WR, et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal [J]. Ann Oncol, 2014, 25(9):1691-1700. DOI: 10.1093/annonc/mdu047.
[4] Galura GM, Cherukuri SV, Hakim N, et al. Acute aleukemic mast cell leukemia:report of a case and review of the literature [J]. Leuk Res Rep, 2020, 14: 100230. DOI: 10.1016/j.lrr.2020.100230.
[5] Chiu A, Orazi A. Mastocytosis and related disorders [J]. Semin Diagn Pathol, 2012, 29(1): 19-30. DOI: 10.1053/j.semdp.2011.06.002.
[6] Costopoulos M, Uzunov M, Bories D, et al Acute mast cell leukemia: a rare but highly aggressive hematopoietic neoplasm [J]. Diagn Cytopathol, 2018, 46(7): 639-641. DOI: 10.1002/dc.23965.
[7] Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis [J]. Mod Pathol, 2011, 24(4): 585-595. DOI: 10.1038/modpathol.2010.224.
[8] Reiter A, George TI, Gotlib J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis [J]. Blood, 2020, 135(16):1365-1376. DOI: 10.1182/blood.2019000932.
[9] Jawhar M, Schwaab J, Schnittger S, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event [J]. Leukemia, 2015, 29(5):1115-1122. DOI: 10.1038/leu.2015.4.
[10] Gilreath JA, Tchertanov L, Deininger MW. Novel approaches to treating advanced systemic mastocytosis [J]. Clin Pharmacol, 2019, 11:77-92. DOI: 10.2147/CPAA.S206615.
[11] Leguit R, Hebeda K, Kremer M, et al. The Spectrum of aggressive mastocytosis: a workshop report and literature review [J]. Pathobiology, 2020, 87(1):2-19. DOI: 10.1159/000504099.
[12] Apsel Winger B, Cortopassi WA, Garrido Ruiz D, et al. ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT [J]. Cancer Res, 2019, 79(16): 4283-4292. DOI: 10.1158/0008-5472.CAN-18-3139.
|